Beskrywing

A rare disease, also referred to as an orphan disease, is any disease that affects a small percentage of the population. There are thousands of rare diseases. To date, six to seven thousand rare diseases have been discovered and new diseases are regularly described in medical literature. The global rare disease diagnostics market in terms of revenue is set to grow by US$ 12 miljard tydens 2021-2027, groei teen 'n saamgestelde jaarlikse groeikoers (CAGR) van 8.6% gedurende die voorspellingsperiode, volgens die data- en ontledingsmaatskappy StrategyHelix. Rising burden of diseases and increase in incidence and prevalence of genetic disorders and various types of cancer, increase in adoption of whole genome and exome sequencing, and increasing research funding and surge in usage for new techniques are driving market growth.

Die verslag verskaf up-to-date markgrootte data vir tydperk 2017-2020 en voorspel tot 2027 covering key market aspects like sales value for rare disease diagnostics. The global rare disease diagnostics market is segmented on the basis of disease, tegnologie, age, analysis target, en streek. By disease, it is categorized into cardiovascular, central nervous system, endocrine and metabolic, hematology, immune and inflammation, rare cancers, and other diseases. The diagnostics for rare cancers segment held the largest market share in 2020. By technology, the rare disease diagnostics market is divided into polymerase chain reaction (PCR), next-generation sequencing, microarrays, en ander. Based on age, the rare disease diagnostics market is divided into children, and adult. Rare disease diagnostics market by analysis target is divided into multiple genes, whole exome, single genes, and whole genome.

The report has profiled some of the key players of the market such as 3billion Inc., Agilent Technologies Inc., BGI Group, Centogene AG, Eurofins Scientific SE, Illumina Inc., Invitae Corporation, Laboratory Corporation of America Holdings, PerkinElmer Inc., Quest Diagnostics Incorporated.

Die verslag is 'n waardevolle hulpbron vir maatskappye en organisasies wat in hierdie bedryf aktief is. It provides a cohesive picture of the rare disease diagnostics market to help drive informed decision making for industry executives, beleidmakers, akademies, en ontleders.

Verslag Omvang

Disease: cardiovascular, central nervous system, endocrine and metabolic, hematology, immune and inflammation, rare cancers, and other diseases
Tegnologie: polymerase chain reaction (PCR), next-generation sequencing, microarrays, en ander
Age: children, and adult
Streek: Noord-Amerika, Asiatiese Stille-Oseaan, Europa, and Rest of the World (ROW)
Analysis target: multiple genes, whole exome, single genes, and whole genome
Jare oorweeg: hierdie verslag dek die tydperk 2017 aan 2027

Sleutelvoordele vir belanghebbendes

Get a comprehensive picture of the global rare disease diagnostics market
Identify regional strategies and strategic priorities on the basis of local data and analysis
Bepaal groeisektore en -neigings vir belegging
Understand what the future of the global rare disease diagnostics market looks like
Identifiseer die mededingende landskap en geleentheidsvenster

INHOUDSOPGAWE

1. Markdefinisie
2. Navorsingsmetodologie
3. Markdata & Outlook
3.1 Markwaarde
3.2 Markwaarde Voorspelling
4. Rare Disease Diagnostics Market by Disease
4.1 Cardiovascular
4.2 Central Nervous System
4.3 Endocrine And Metabolic
4.4 Hematology
4.5 Immune And Inflammation
4.6 Rare Cancers
4.7 Other Diseases
5. Rare Disease Diagnostics Market by Technology
5.1 Polymerase Chain Reaction (Pcr)
5.2 Next-Generation Sequencing
5.3 Microarrays
5.4 Ander
6. Rare Disease Diagnostics Market by Age
6.1 Children
6.2 Adult
7. Rare Disease Diagnostics Market by Analysis Target
7.1 Multiple Genes
7.2 Whole Exome
7.3 Single Genes
7.4 Whole Genome
8. Rare Disease Diagnostics Market by Region
8.1 Noord-Amerika
8.2 Asiatiese Stille-Oseaan
8.3 Europa
8.4 Rest Of The World (Row)
9. Maatskappy profiele
9.1 3billion Inc.
9.2 Agilent Technologies Inc.
9.3 BGI Group
9.4 Centogene AG
9.5 Eurofins Scientific SE
9.6 Illumina Inc.
9.7 Invitae Corporation
9.8 Laboratory Corporation of America Holdings
9.9 PerkinElmer, Inc.
9.10 Quest Diagnostics Incorporated
10. Bylaag
10.1 Oor StrategyHelix
10.2 Vrywaring